Biomarker & Intervention Discovery

Inflammatory Bowel Disease (Crohn's/UC)

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ATG16L1 1FOXP3 2IL10 20IL12B 14IL23A 8IL23R 178ITGA4 9JAK1 30JAK2 256MADCAM1 2NOD2 202S1PR1 211TNF 91TYK2 216
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ADALIMUMAB ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
EPIRUBICIN ? unclear Mechanistic
METHOTREXATE ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
EFAVIRENZ ? unclear Mechanistic
ANESTHETIC AGENT ? unclear Mechanistic
ACYCLOVIR ? unclear Mechanistic
MACROLIDE ANTIBIOTIC ? unclear Mechanistic
LISOFYLLINE ? unclear Mechanistic
PROTON PUMP INHIBITOR ? unclear Mechanistic
SCH-708980 inhibits Mechanistic
SIROLIMUS ? unclear Mechanistic
SHO-SAIKO-TO ? unclear Mechanistic
RABEPRAZOLE ? unclear Mechanistic
AMOXICILLIN ANHYDROUS ? unclear Mechanistic
CLARITHROMYCIN ? unclear Mechanistic
ILODECAKIN ? unclear Mechanistic
FLUTICASONE ? unclear Mechanistic
TRETINOIN ? unclear Mechanistic
MESALAMINE ? unclear Mechanistic
ROFECOXIB ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
PEGILODECAKIN ? unclear Mechanistic
ZIDOVUDINE ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TILDRAKIZUMAB inhibits Mechanistic
EGEN-001 ? unclear Mechanistic
USTEKINUMAB inhibits Mechanistic
BRAZIKUMAB inhibits Mechanistic
GUSELKUMAB inhibits Mechanistic
BRIAKINUMAB inhibits Mechanistic
ISOPROTERENOL ? unclear Mechanistic
EBDAROKIMAB inhibits Mechanistic
HUMANIZED SMART ANTI-IL-12 ANTIBODY ? unclear Mechanistic
ADENOVIRAL TRANSDUCED HIL-12-EXPRESSING AUTOLOGOUS DENDRITIC CELLS INXN-3001 PLUS ACTIVATOR LIGAND INXN-1001 ? unclear Mechanistic
VIRULIZIN ? unclear Mechanistic
RISANKIZUMAB inhibits Mechanistic
MIRIKIZUMAB inhibits Mechanistic
INFLIXIMAB ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
USTEKINUMAB inhibits Mechanistic
RISANKIZUMAB inhibits Mechanistic
MIRIKIZUMAB inhibits Mechanistic
BRAZIKUMAB inhibits Mechanistic
TILDRAKIZUMAB inhibits Mechanistic
GUSELKUMAB inhibits Mechanistic
EBDAROKIMAB inhibits Mechanistic
BRIAKINUMAB inhibits Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
INFLIXIMAB ? unclear Mechanistic
AZATHIOPRINE ? unclear Mechanistic
CELECOXIB ? unclear Mechanistic
CHEMBL4206167 inhibits Mechanistic 1.81 nM (Kd)
CHEMBL4567228 inhibits Mechanistic 113.0 nM (IC50)
CHEMBL4555885 inhibits Mechanistic 32.0 nM (IC50)
CHEMBL4529484 inhibits Mechanistic 25.0 nM (IC50)
CHEMBL4577218 inhibits Mechanistic 39.0 nM (IC50)
CHEMBL4442232 inhibits Mechanistic 892.0 nM (IC50)
CHEMBL4565015 inhibits Mechanistic 37.0 nM (IC50)
CHEMBL4515769 inhibits Mechanistic 199.0 nM (IC50)
CHEMBL4451305 inhibits Mechanistic 79.0 nM (IC50)
CHEMBL4441983 inhibits Mechanistic 220.0 nM (IC50)
CHEMBL4537768 inhibits Mechanistic 102.0 nM (IC50)
CHEMBL4458363 inhibits Mechanistic 78.0 nM (IC50)
CHEMBL4454287 inhibits Mechanistic 183.0 nM (IC50)
CHEMBL4452903 inhibits Mechanistic 57.0 nM (IC50)
CHEMBL4457621 inhibits Mechanistic 52.0 nM (IC50)
CHEMBL4543753 inhibits Mechanistic 518.0 nM (IC50)
CHEMBL4527549 inhibits Mechanistic 153.0 nM (IC50)
CHEMBL4540496 inhibits Mechanistic 223.0 nM (IC50)
CHEMBL4524632 inhibits Mechanistic 79.0 nM (IC50)
CHEMBL4459265 inhibits Mechanistic 124.0 nM (IC50)
CHEMBL4550853 inhibits Mechanistic 2584.0 nM (IC50)
CHEMBL4435141 inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4446365 inhibits Mechanistic 100.0 nM (IC50)
CHEMBL4462185 inhibits Mechanistic 96.0 nM (IC50)
CHEMBL4454702 inhibits Mechanistic 99.0 nM (IC50)
CHEMBL4576008 inhibits Mechanistic 95.0 nM (IC50)
CHEMBL4589681 inhibits Mechanistic 107.0 nM (IC50)
CHEMBL4583420 inhibits Mechanistic 101.0 nM (IC50)
CHEMBL4440544 inhibits Mechanistic 107.0 nM (IC50)
CHEMBL4564118 inhibits Mechanistic 47.0 nM (IC50)
CHEMBL4537038 inhibits Mechanistic 59.0 nM (IC50)
CHEMBL4547985 inhibits Mechanistic 206.0 nM (IC50)
CHEMBL4558328 inhibits Mechanistic 40.0 nM (IC50)
CHEMBL4567670 inhibits Mechanistic 139.0 nM (IC50)
CHEMBL4582731 inhibits Mechanistic 1885.0 nM (IC50)
CHEMBL4435308 inhibits Mechanistic 134.0 nM (IC50)
CHEMBL4564607 inhibits Mechanistic 48.0 nM (IC50)

Showing top 40 of 178 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
SENKTIDE ? unclear Mechanistic
VEDOLIZUMAB inhibits Mechanistic
R1295 ? unclear Mechanistic
ABRILUMAB inhibits Mechanistic
UCB-1184197 inhibits Mechanistic
ATL1102 ? unclear Mechanistic
NATALIZUMAB inhibits Mechanistic
FIRATEGRAST inhibits Mechanistic
BIO1211 ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RUXOLITINIB inhibits Mechanistic
IZENCITINIB inhibits Mechanistic
PEMBROLIZUMAB ? unclear Mechanistic
RUXOLITINIB PHOSPHATE inhibits Mechanistic
GOLIDOCITINIB inhibits Mechanistic
FILGOTINIB MALEATE inhibits Mechanistic
MOMELOTINIB inhibits Mechanistic
AZD1480 inhibits Mechanistic
DELGOCITINIB inhibits Mechanistic
TRICETAMIDE inhibits Mechanistic
TOFACITINIB inhibits Mechanistic
PEFICITINIB inhibits Mechanistic
BREPOCITINIB inhibits Mechanistic
UPADACITINIB HEMIHYDRATE inhibits Mechanistic
CYCLOSPORINE ? unclear Mechanistic
INCB-047986 inhibits Mechanistic
ABROCITINIB inhibits Mechanistic
ENZASTAURIN ? unclear Mechanistic
CERDULATINIB inhibits Mechanistic
NEZULCITINIB inhibits Mechanistic
FILGOTINIB inhibits Mechanistic
GLPG-0555 inhibits Mechanistic
SOLCITINIB inhibits Mechanistic
GUSACITINIB inhibits Mechanistic
ITACITINIB inhibits Mechanistic
BARICITINIB inhibits Mechanistic
MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE ? unclear Mechanistic
DEURUXOLITINIB PHOSPHATE ? unclear Mechanistic
TOFACITINIB CITRATE ? unclear Mechanistic
UPADACITINIB ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TYRPHOSTIN 23 ? unclear Mechanistic
AZD1480 inhibits Mechanistic
PF-562271 ? unclear Mechanistic
JAK2V617F INHIBITOR INCB160058 ? unclear Mechanistic
PEMBROLIZUMAB ? unclear Mechanistic
TOFACITINIB inhibits Mechanistic 11.0 nM (IC50)
RUXOLITINIB inhibits Mechanistic
FEDRATINIB inhibits Mechanistic
TENALISIB ? unclear Mechanistic
FILGOTINIB inhibits Mechanistic
PACRITINIB inhibits Mechanistic
BARICITINIB inhibits Mechanistic
NS-018 inhibits Mechanistic
TANESPIMYCIN ? unclear Mechanistic
AZD1208 ? unclear Mechanistic
PICTILISIB ? unclear Mechanistic
DOVITINIB ? unclear Mechanistic 7000.0 nM (Kd)
AZ960 ? unclear Mechanistic
GANDOTINIB inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
LUMINESPIB ? unclear Mechanistic
ROPEGINTERFERON ALFA-2B ? unclear Mechanistic
MOMELOTINIB inhibits Mechanistic
AZD-1480 inhibits Mechanistic
NEZULCITINIB inhibits Mechanistic
TYRPHOSTIN AG 555 ? unclear Mechanistic
GELDANAMYCIN ? unclear Mechanistic
CHEMBL:CHEMBL546797 ? unclear Mechanistic
ERLOTINIB ? unclear Mechanistic 4000.0 nM (IC50)
BINIMETINIB ? unclear Mechanistic
PD-0166285 ? unclear Mechanistic
SGI-1776 ? unclear Mechanistic
XL-019 inhibits Mechanistic
THIRAM ? unclear Mechanistic
RIBOCICLIB ? unclear Mechanistic
ALFENTANIL HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL29197 ? unclear Mechanistic
CEP-11981 ? unclear Mechanistic
DACTOLISIB ? unclear Mechanistic
AT-9283 inhibits Mechanistic 1.2 nM (IC50)

Showing top 40 of 256 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ONTAMALIMAB inhibits Mechanistic
NAVARIXIN ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
INARIGIVIR SOPROXIL ? unclear Mechanistic
CHEMBL:CHEMBL1351908 ? unclear Mechanistic
CHEMBL:CHEMBL585502 ? unclear Mechanistic
CHEMBL:CHEMBL577660 ? unclear Mechanistic
MICROPARTICLE MDP/BACTERIAL DNA-CONTAINING MIS416 ? unclear Mechanistic
CYCLOVALONE ? unclear Mechanistic 9950.0 nM (EC50)
CHEMBL:CHEMBL1456848 ? unclear Mechanistic
CHEMBL:CHEMBL599890 ? unclear Mechanistic
MIFAMURTIDE ? unclear Mechanistic
CHEMBL:CHEMBL578944 ? unclear Mechanistic
MURABUTIDE ? unclear Mechanistic
ANHYDROUS TACROLIMUS ? unclear Mechanistic
CHEMBL:CHEMBL590706 ? unclear Mechanistic
CYCLOSPORINE ? unclear Mechanistic
CHEMBL1542558 inhibits Mechanistic 16600.0 nM (IC50)
CHEMBL1717353 inhibits Mechanistic 8440.0 nM (IC50)
CHEMBL1373066 inhibits Mechanistic 17300.0 nM (IC50)
CHEMBL1586616 inhibits Mechanistic 3990.0 nM (IC50)
CHEMBL1708503 inhibits Mechanistic 1720.0 nM (IC50)
CHEMBL1312200 inhibits Mechanistic 7040.0 nM (IC50)
CHEMBL599890 inhibits Mechanistic 19700.0 nM (IC50)
CHEMBL1561275 inhibits Mechanistic 5900.0 nM (IC50)
CHEMBL1405985 inhibits Mechanistic 2930.0 nM (IC50)
CHEMBL1543504 inhibits Mechanistic 5900.0 nM (IC50)
CHEMBL1710033 inhibits Mechanistic 1620.0 nM (IC50)
CHEMBL1729430 inhibits Mechanistic 7930.0 nM (IC50)
CHEMBL1519375 inhibits Mechanistic 16900.0 nM (IC50)
CHEMBL1388356 inhibits Mechanistic 17800.0 nM (IC50)
CHEMBL1700643 inhibits Mechanistic 15300.0 nM (IC50)
CHEMBL1719980 inhibits Mechanistic 19000.0 nM (IC50)
CHEMBL1314048 inhibits Mechanistic 11700.0 nM (IC50)
CHEMBL1508723 inhibits Mechanistic 6080.0 nM (IC50)
CHEMBL1542483 inhibits Mechanistic 9140.0 nM (IC50)
CHEMBL1599782 inhibits Mechanistic 12000.0 nM (IC50)
CHEMBL1491541 inhibits Mechanistic 11400.0 nM (IC50)
CHEMBL1712022 inhibits Mechanistic 18500.0 nM (IC50)
CHEMBL1529494 inhibits Mechanistic 8210.0 nM (IC50)
CHEMBL1299637 inhibits Mechanistic 2160.0 nM (IC50)
CHEMBL1426966 inhibits Mechanistic 6900.0 nM (IC50)
CHEMBL1731774 inhibits Mechanistic 1120.0 nM (IC50)

Showing top 40 of 202 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CHEMBL:CHEMBL171699 ? unclear Mechanistic
(S)-FTY720P ? unclear Mechanistic
CHEMBL:CHEMBL1362503 ? unclear Mechanistic
SAR247799 ? unclear Mechanistic
ASP-4058 ? unclear Mechanistic
MOCRAVIMOD HYDROCHLORIDE ? unclear Mechanistic
BMS-986104 ? unclear Mechanistic
PONESIMOD activates Mechanistic
ISOVELLERAL ? unclear Mechanistic
SIPONIMOD activates Mechanistic
AMISELIMOD HYDROCHLORIDE ~ modulates Mechanistic
GSK-2018682 ? unclear Mechanistic
FINGOLIMOD LAURYL SULFATE ~ modulates Mechanistic
FINGOLIMOD HYDROCHLORIDE activates Mechanistic
CHEMBL:CHEMBL586135 ? unclear Mechanistic
OZANIMOD HYDROCHLORIDE ~ modulates Mechanistic
CHEMBL:CHEMBL579318 ? unclear Mechanistic
KRP203 activates Mechanistic
AMISELIMOD ? unclear Mechanistic
CENERIMOD ~ modulates Mechanistic
9,10-PHENANTHRENEQUINONE ? unclear Mechanistic
ETRASIMOD ARGININE ~ modulates Mechanistic
ETRASIMOD activates Mechanistic
SIPONIMOD FUMARIC ACID activates Mechanistic
OZANIMOD ? unclear Mechanistic
FINGOLIMOD ? unclear Mechanistic
SONEPCIZUMAB ? unclear Mechanistic
PINAFIDE ? unclear Mechanistic
CHEMBL117910 inhibits Mechanistic 1.4 nM (IC50)
CHEMBL332050 activates Mechanistic 82.0 nM (EC50)
CHEMBL115505 activates Mechanistic 322.1 nM (EC50)
CHEMBL115344 activates Mechanistic 260.0 nM (EC50)
CHEMBL324358 activates Mechanistic 598.4 nM (EC50)
CHEMBL332472 activates Mechanistic 12.7 nM (EC50)
CHEMBL422074 activates Mechanistic 58.0 nM (EC50)
CHEMBL225155 activates Mechanistic 0.9 nM (EC50)
CHEMBL116953 activates Mechanistic 130.0 nM (EC50)
CHEMBL334038 activates Mechanistic 8.6 nM (EC50)
CHEMBL325408 activates Mechanistic 1805.0 nM (EC50)
CHEMBL114031 activates Mechanistic 550.0 nM (EC50)

Showing top 40 of 211 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
NERELIMOMAB inhibits Mechanistic
CROMOLYN SODIUM ? unclear Mechanistic
PLACULUMAB inhibits Mechanistic
METHYLENE BLUE ? unclear Mechanistic
ALTEPLASE ? unclear Mechanistic
CARBOPLATIN ? unclear Mechanistic
GENTAMICIN ? unclear Mechanistic
GOLIMUMAB inhibits Mechanistic
BUPIVACAINE ? unclear Mechanistic
PENTOXIFYLLINE ? unclear Mechanistic
BENZO[E]PYRENE ? unclear Mechanistic
THALIDOMIDE ? unclear Mechanistic
PYRAZINAMIDE ? unclear Mechanistic
GLIMEPIRIDE ? unclear Mechanistic
OMEPRAZOLE ? unclear Mechanistic
LENERCEPT inhibits Mechanistic
ADALIMUMAB inhibits Mechanistic
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic
REMTOLUMAB ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
LENABASUM ? unclear Mechanistic
MAGNESIUM SULFATE ANHYDROUS ? unclear Mechanistic
PICIBANIL ? unclear Mechanistic
FLUOCINOLONE ACETONIDE ? unclear Mechanistic
MILTEFOSINE ? unclear Mechanistic
HOMIDIUM BROMIDE ? unclear Mechanistic
OZORALIZUMAB inhibits Mechanistic
PEGSUNERCEPT inhibits Mechanistic
CERTOLIZUMAB PEGOL inhibits Mechanistic
THERAPEUTIC HORMONE ? unclear Mechanistic
NAFAMOSTAT ? unclear Mechanistic
FOLIC ACID ? unclear Mechanistic
ABBV-257 ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
COVA322 ? unclear Mechanistic
HYDROXYCHLOROQUINE ? unclear Mechanistic
CERTOLIZUMAB ? unclear Mechanistic
AN0128 ? unclear Mechanistic
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic
SORAFENIB ? unclear Mechanistic

Showing top 40 of 91 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
LORPUCITINIB inhibits Mechanistic
FILGOTINIB inhibits Mechanistic
RG-1530 ? unclear Mechanistic
ZOTIRACICLIB inhibits Mechanistic
SAR-20347 inhibits Mechanistic
DEUCRAVACITINIB ~ modulates Mechanistic
CERDULATINIB inhibits Mechanistic
COMPOUND 6 [PMID: 34333981] inhibits Mechanistic
RUXOLITINIB inhibits Mechanistic 19.0 nM (IC50)
OCLACITINIB inhibits Mechanistic
GDC-0214 inhibits Mechanistic
JNJ-7706621 ? unclear Mechanistic 32.0 nM (Kd)
BREPOCITINIB inhibits Mechanistic
IZENCITINIB inhibits Mechanistic
2-TERT-BUTYL-9-FLUORO-1,6-DIHYDROBENZO[H]IMIDAZO[4,5-F]ISOQUINOLIN-7-ONE inhibits Mechanistic
PF-562271 ? unclear Mechanistic
UPADACITINIB HEMIHYDRATE inhibits Mechanistic
JAK3 INHIBITOR 34 inhibits Mechanistic
UPADACITINIB inhibits Mechanistic
DOVITINIB ? unclear Mechanistic 150.0 nM (Kd)
ROPSACITINIB inhibits Mechanistic
GOLIDOCITINIB inhibits Mechanistic
COMPOUND 13AC [PMID: 33256400] inhibits Mechanistic
TYK2 INHIBITOR 18 [WO2023227946] ~ modulates Mechanistic
TAMATINIB ? unclear Mechanistic
CYC-116 ? unclear Mechanistic 79.43 nM (Ki)
PF-06263276 inhibits Mechanistic
GO-6976 ? unclear Mechanistic
SJ988497 ? unclear Mechanistic
PEFICITINIB inhibits Mechanistic
NVP-TAE684 ? unclear Mechanistic
COMPOUND 25AP [PMID: 37796543] inhibits Mechanistic
HESPERADIN inhibits Mechanistic 75.0 nM (Kd)
COMPOUND 29 [MOSLIN ET AL., 2017] inhibits Mechanistic
ALDESLEUKIN ? unclear Mechanistic
BMS-986202 inhibits Mechanistic
SOLCITINIB inhibits Mechanistic
MOMELOTINIB inhibits Mechanistic
FEDRATINIB inhibits Mechanistic 150.0 nM (IC50)
BMS-911543 inhibits Mechanistic

Showing top 40 of 216 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT04844606 Phase: PHASE3 Started: 2021-05-26

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continu...

NCT06405087 Phase: PHASE3 Started: 2025-10-27

The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time. Other aims are to understand if the long time use of vedolizumab SC has an impact on the time period until hospital visits ...

NCT07632573 Phase: PHASE1 Started: 2026-05-18

A Phase 1, 2-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of BDHK-2009 (Part 1) and multiple oral doses (Part 2) of BDHK-200 in healthy adult participants.

NCT07237516 Phase: N/A Started: 2025-11-20

The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed Zymfentra (IFX-dyyb...

NCT06764615 Phase: PHASE2 Started: 2025-05-28

Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension ...

NCT03196427 Phase: PHASE2 Started: 2018-07-30

The purpose of this study is to determine the safety profile of long-term vedolizumab IV treatment in pediatric participants with UC or CD.

NCT07431983 Phase: N/A Started: 2026-03-01

Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, steril...

NCT05442567 Phase: PHASE3 Started: 2023-05-16

The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

NCT05384080 Phase: N/A Started: 2022-08-08

The primary reason of this study is to observe current treatment options in participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Poland. There is no treatment involved in this study, this is only an observational review of ongoing/initiating treatment data relating t...

NCT07524244 Phase: NA Started: 2026-02-17

This study is a randomized controlled clinical trial evaluating whether two therapeutic dietary approaches - a ketogenic diet and a carnivore (lion) diet - can improve quality of life, reduce symptoms, and influence measures of disease activity in adults with inflammatory bowel disease \[ulcerative ...

NCT07113522 Phase: PHASE2 Started: 2025-06-26

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

NCT07385131 Phase: N/A Started: 2025-10-08

This comparative observational cohort clinical study aims to investigate the necessity of premedication for allergy prevention prior to infliximab injection, and is designed to evaluate whether non-routine administration of dexamethasone before intravenous infusion of infliximab yields greater benef...

NCT04522271 Phase: NA Started: 2020-08-25

The purpose of the study is determine if a plant-based resistant starch that is optimized for the individual will target the underlying cause of inflammatory bowel disease and restore a "healthier" gut microbiome in pediatric participants with inflammatory bowel disease.

NCT06896305 Phase: NA Started: 2025-05-22

This clinical study protocol aims to prospectively compare the efficacy of standard therapy with anti-TNF agents combined with the Crohn's Disease Exclusion Diet (CDED) versus anti-TNF therapy alone in adult patients with active Crohn's disease or ulcerative colitis. The study will involve patients...

NCT01169194 Phase: N/A Started: 2003-06

The investigators are doing the research to discover genes that cause Inflammatory Bowel Disease (IBD) specifically in the African American population. African Americans with or without Crohn's disease or ulcerative colitis are eligible to join. If you agree to join the study, the investigators will...


Agents Found By Disease-Level Search

Searched directly from “Inflammatory Bowel Disease (Crohn's/UC)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 14-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

28 agents shown (approved or with trial evidence) — 22 not found by the gene-target search above.

Vedolizumab

· 4 trials · source: ClinicalTrials.gov
NCT03196427 NCT03138655 NCT07273760

Anti-TNF TherapyNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT03090139 NCT06896305

Mirikizumab

· 2 trials · source: ClinicalTrials.gov
NCT04844606 NCT04844606

Fecal Microbiota Transplantation (FMT)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02108821

Upadacitinib

· 1 trial · source: ClinicalTrials.gov
NCT06922331

Ustekinumab 90 mg SC q8wNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07303686

Ustekinumab 90 mg SC q12wNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07303686

Risankizumab

· 1 trial · source: ClinicalTrials.gov
NCT04254783

Cytochrome P450 (CYP) SubstratesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04254783

Vedolizumab IVNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05442567

PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem CellsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05039411

Vitamin D3NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01877577

Multispectral Optoacoustic Tomography (MSOT)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04650867

Ketogenic dietNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07524244

Carnivore (Lion) DietNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07524244

Zasocitinib

· 1 trial · source: ClinicalTrials.gov
NCT06764615

Adalimumab

· 1 trial · source: ClinicalTrials.gov
NCT04089514

Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samplesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01364896

Dexamethasone (IV)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07385131

InflectraNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03801928

MT-501NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07113522

MT-201NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07113522

CDED (Crohn's Disease Exclusion Diet) in addition to anti-TNF therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06896305

UTTR1147ANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02749630

BDHK-2009 TabletsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07632573

Vedolizumab SCNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06405087

AB (antibiotics)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02033408

CS (corticosteroids) OnlyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02033408

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.